Reduces Severe OM
Keeps patients on treatment by lowering the severity, incidnece, and duration of oral mucositis
A CLINICALLY VALIDATED APPROACH
Meaningful improvement. Practical delivery.
Mureva was designed to address both sides of the challenge: the clinical burden of oral mucositis and the operational barrier have limited routine PBM adoption.
Protects Patient Function
Helps preserve swallowing and taste, reduces feeding tube dependence, and supports patient recovery
Simplifies PBM Delivery
Delivers a standardized, repeatable 10-minute daily treatment with minimal set up
RANDOMIZED, DOUBLE-BLIND, SHAM- CONTROLLED PIVOTAL TRIAL
A clear reduction in severe oral mucositis
Severe OM through two weeks post-IMRT in the FDA-indicated subgroup (n=40)
54% RELATIVE REDUCTION
A SIMPLER WAY TO DELIVER PBM
One appointment. One connected workflow.
Mureva uses dual, soft, and flexible intraoral mouthpieces to reach tissues most susceptible to developing OM. Treatment is delivered immeditely before radiation.
01
Patient arrives
PBM is scheduled prior to patient’s daily radiation
02
Complete Mureva
10-minute treatment under trained supervision
03
Proceed to radiation
No change to the patient’s radiation delivery
DESIGNED FOR ROUTINE CLINICAL USE
Built around the way cancer centers already work
Mureva can be implemented within existing ARIA workflows for ease of scheduling, charge capture, and quality assurance
